The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.
Current vaccine strategies against the asexual blood stage of Plasmodium falciparum are mostly focused on well-studied merozoite antigens that induce immune responses after natural exposure, but have yet to induce robust protection in any clinical trial. Here we compare human-compatible viral-vector...
Main Authors: | Douglas, A, Williams, A, Illingworth, J, Kamuyu, G, Biswas, S, Goodman, A, Wyllie, D, Crosnier, C, Miura, K, Wright, G, Long, C, Osier, F, Marsh, K, Turner, A, Hill, A, Draper, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2011
|
Similar Items
-
Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5.
by: Douglas, A, et al.
Published: (2014) -
A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants
by: Bustamante, L, et al.
Published: (2013) -
Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.
by: Williams, A, et al.
Published: (2012) -
A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.
by: Douglas, A, et al.
Published: (2015) -
The erythrocyte binding antigens and PfRh proteins are targets of Plasmodium falciparum invasioninhibitory antibodies.
by: Persson, K, et al.
Published: (2008)